Neurofeedback From the Supplementary Motor Area for Tourette Syndrome

Not Applicable

Recruiting

• Conditions: Tourette Syndrome in Adolescence
• Interventions: Other: Neurofeedback from the SMA; Other: Neurofeedback from control region

• Registration Number: NCT05558566
• Lead Sponsor: Yale University

Brief Summary

This is a clinical trial where adolescents aged 10-16 years old with Tourette Syndrome (or chronic tic disorder) are randomized to receive either real-time functional magnetic resonance imaging (fMRI) neurofeedback targeting the supplementary motor area (for the experimental intervention) or real-time fMRI neurofeedback (NF) from a control region (for the control intervention).

Detailed Description

The training portion of this study involves three fMRI NF sessions, with six NF scans per session. NF scans alternate between up-regulate and down-regulate blocks in which participants are cued to increase or decrease activity in the target region while receiving feedback on activity in the region at the bottom of the screen in the form of a line graph. The experimental group receives feedback from the supplementary motor area (SMA) and the control group receives feedback from a control region of the brain.

Study Timeline

• Study First Submitted: 2022-09-21
• Study First Submitted QC: 2022-09-23
• Study First Posted: 2022-09-28
• Study Start: 2022-11-01
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-09
• Last Update Posted: 2024-08-13
• Primary Completion: 2026-12-20
• Study Completion: 2027-01-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

• Boys and girls, 10 to 16 years of age
• A current diagnosis of Tourette Syndrome (TS) or chronic tic disorder (CTD), with active tics that can be executed without head movement, and a YGTSS score of at least 13 (for TS participants) or at least 12 (for CTD participants)
• Currently stable medication treatment and no planned changes in medication for the duration of the study.
• Family residence within 2 hours of Yale Medical Center with ability and willingness to attend assessment and fMRI visits.
• Children and their parents are expected to be able to speak and understand spoken English in order to participate in a clinical assessment of TS and related psychopathology.
• Subjects will be free of: 1) metal medical implants or braces, 2) pregnancy, and will have 3) a body weight of less than 250 lbs. and 4) no claustrophobia.

Exclusion Criteria

• Intelligence quotient below 80
• Current diagnosis of autism spectrum disorder, bipolar or psychotic disorder or current suicidality
• Significant medical condition such as heart disease, hypertension, liver or renal failure, pulmonary disease, seizure disorder
• Recently initiated psychotherapy. Participation in the study will not be allowed within 8 weeks of the initiation of psychotherapy. Ongoing, concurrent psychotherapy (that was initiated at least 8 weeks previously) for the child will be allowed, but parents will be asked not to initiate any new psychotherapy for the child during the study
• Subjects may also be excluded after the first MR scan if we are unable to localize the two regions in their brain that are used as targets for the active and control neurofeedback conditions.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Neurofeedback from the SMA	Neurofeedback from the SMA	-
Neurofeedback from control region	Neurofeedback from control region	-

Primary Outcome Measures

Name	Time	Method
Change in symptoms after the intervention compared to baseline	Baseline, 4 days post-NF, 2 weeks post-NF, and 1 month post-NF	Symptom severity is assessed using the Yale Global Tic Severity Scale (YGTSS) before NF and at several time points in the month following the completion of NF training.

Secondary Outcome Measures

Name	Time	Method
Change in control over activity in the SMA target region during NF compared to baseline	Baseline and during NF	Control over the SMA is computed as the difference in the blood-oxygenation-level-dependent (BOLD) signal in SMA during up-regulate compared to down-regulate blocks. This measure is computed both in the NF scans and in the control task scans prior to the start of NF. Improvement in control for each subject is the difference of these two (i.e., control during NF minus control during pre-intervention control task scans).

Trial Locations

Locations (1)

Yale University School of Medicine; 🇺🇸 New Haven, Connecticut, United States